As part of his Ph.D. in pharmacy at Université Laval, Dr. Audet-Walsh focused on the link between steroid hormones and endometrial and prostate cancers. During his work, he has demonstrated that the regulation of steroid metabolism is altered in tumor cells, notably via alterations of specific metabolic pathways. In addition, several pharmacogenomic analyses have been able to establish the link between genetic markers in steroidogenesis genes in relationship with prostate cancer progression. He then undertook a postdoctoral fellowship at McGill University, where he studied transcriptional regulation mechanisms by members of the nuclear receptor family using transcriptomic, cistromic (functional genomic) and metabolomic tools in different in vitro and in vivo models, with a particular interest in the regulation of energy metabolism. Dr. Audet-Walsh has notably demonstrated the interaction between several nuclear receptors and different cell signaling pathways in the transcriptional control of cell metabolism following various stresses. In addition, he was interested in characterizing the different waves of transcriptional regulation that involve the functional interaction between different families of transcription factors, especially in hormone-sensitive cancers.

Recently recruited at the Centre de recherche du CHU de Québec – Laval University, Dr. Audet-Walsh specializes in the study of metabolic reprogramming in hormone-sensitive cancers, by nuclear receptors. By their actions, these receptors act as master regulators of the cellular bioenergetic pathways, necessary for both the synthesis of ATP and the biosynthesis of macromolecules that are essential to cell proliferation. By using transcriptomic, cistromic and metabolomic analyzes, he wants to understand how these receptors contribute to the transcriptional regulation of different cellular metabolic pathways in physiology and disease. In addition, he also wants to understand how metabolism in turn influences hormonal signaling, since several metabolic intermediates are essential for the regulation of the epigenome. Finally, a translational research approach targeting the key elements of metabolism in pathological conditions will be used to validate its results in a context of in vitro (cells in culture) and in vivo (rodent models, human samples) models. Understanding the metabolic reprogramming associated with pathological conditions, as well as the factors that control such reprogramming, will allow the identification of new therapeutic targets in different hormone-sensitive cancers.

CHUL
2705 Boulevard Laurier
R-4714
Québec, QC
Canada G1V 4G2
40 entries « 1 of 4 »

Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Lacombe L, Laverdière I, Atallah C, Pouliot F, Audet-Walsh É

Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Journal Article

Mol Metab, 62 , 2022.

Abstract | Links:

Laurin KM, Coutu-Beaudry K, Salazar A, Méribout N, Audet-Walsh É, Gravel SP

Low expression of PGC-1β and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1

Journal Article

Cancer Lett, 541 , 2022.

Abstract | Links:

Loehr J, Kougnassoukou Tchara PE, Gonthier K, Noufi C, Linteau N, Audet-Walsh É, Lambert JP

A Nutrient-Based Cellular Model to Characterize Acetylation-Dependent Protein-Protein Interactions

Journal Article

Front Mol Biosci, 9 , 2022.

Abstract | Links:

Bramhecha YM, Guérard KP, Audet-Walsh É, Rouzbeh S, Kassem O, Pernet E, Scarlata E, Hamel L, Brimo F, Divangahi M, Aprikian AG, Chevalier S, Giguère V, Lapointe J

Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients

Journal Article

Oncogene, 41 (20), 2022.

Abstract | Links:

Lacouture A, Lafront C, Peillex C, Pelletier M, Audet-Walsh É

Impacts of endocrine-disrupting chemicals on prostate function and cancer

Journal Article

Environ Res, 204 (Pt B), 2022.

Abstract | Links:

Paquette M, Yan M, Ramírez-Reyes JMJ, El-Houjeiri L, Biondini M, Dufour CR, Jeong H, Pacis A, Giguère V, Estall JL, Siegel PM, Audet-Walsh É, Pause A

Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Lacouture A, Jobin C, Weidmann C, Berthiaume L, Bastien D, Laverdière I, Pelletier M, Audet-Walsh É

A FACS-Free Purification Method to Study Estrogen Signaling, Organoid Formation, and Metabolic Reprogramming in Mammary Epithelial Cells

Journal Article

Front Endocrinol (Lausanne), 12 , 2021.

Abstract | Links:

Poluri RTK, Paquette V, Allain ÉP, Lafront C, Joly-Beauparlant C, Weidmann C, Droit A, Guillemette C, Pelletier M, Audet-Walsh É

KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism

Journal Article

Endocr Relat Cancer, 28 (4), 2021.

Abstract | Links:

Audet-Walsh É, Vernier M, Viollet B

Editorial: AMPK and mTOR Beyond Signaling: Emerging Roles in Transcriptional Regulation

Journal Article

Front Cell Dev Biol, 8 , 2020.

| Links:

Lafront C, Germain L, Weidmann C, Audet-Walsh E

A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation

Journal Article

Sci Rep, 10 (1), 2020.

Abstract | Links:

40 entries « 1 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Canada Research Chair in Targeting metabolic vulnerabilities for the treatment of hormone-sensitive cancers, from 2020-07-01 to 2025-06-30
  • Functional interaction between the androgen and the estrogen signalling pathways in prostate cancer, from 2018-10-01 to 2023-03-31
  • Génomique fonctionnelle des récepteurs aux hormones stéroïdiennes dans le contrôle du métabolisme énergétique des cellules de cancer de la prostate, from 2019-07-01 to 2023-06-30
  • Inhibition of the AMPK metabolic program for the treatment of prostate cancer, from 2019-08-01 to 2022-07-31
  • Regulation of Cellular Energy Metabolism in Mammary Epithelial Cells, from 2019-04-01 to 2024-03-31
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2023-01-14

Recently finished projects

  • Bourse de soutien aux nouveaux détenteurs de Chaire de recherche du Canada, from 2020-07-01 to 2022-06-30
  • Deciphering the role of KLF5 and NFYA in prostate cancer, from 2018-09-01 to 2021-08-31
  • Étude de criblage sur la reprogrammation du métabolisme, du micro-environnement tumoral et des cellules souches cancéreuses dans le médulloblastome, from 2021-05-01 to 2022-04-30
  • Targeting metabolic vulnerabilities for the treatment of prostate cancer, from 2019-07-01 to 2021-12-31
Data provided by the Université Laval research projects registery